Phospholipase C\(\gamma\) in Distinct Regions of the Ventral Tegmental Area Differentially Modulates Mood-Related Behaviors

Carlos A. Bolaños,\(^1\) Linda I. Perrotti,\(^1\) Scott Edwards,\(^1\) Amelia J. Eisch,\(^1\) Michel Barrot,\(^1\) Valerie G. Olson,\(^1\) David S. Russell,\(^2\) Rachael L. Neve,\(^3\) and Eric J. Nestler\(^1\)

\(^1\)Department of Psychiatry and Center for Basic Neuroscience, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9070, \(^2\)Departments of Psychiatry and Neurology, Yale University School of Medicine, New Haven, Connecticut 06508, and \(^3\)McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478

Neurotrophic factor signaling pathways modulate cellular and behavioral responses to drugs of abuse. In addition, chronic exposure to morphine increases expression of phospholipase C\(\gamma1\) (PLC\(\gamma1\)) (a protein involved in neurotrophic signaling) in the ventral tegmental area (VTA), a neural substrate for many drugs of abuse. Using viral-mediated gene transfer to locally alter the activity of PLC\(\gamma1\), we show that overexpression of PLC\(\gamma1\) in rostral portions of the VTA (R-VTA) results in increased morphine place preference, whereas PLC\(\gamma1\) overexpression in the caudal VTA (C-VTA) results in avoidance of morphine-paired compartments. In addition, overexpression of PLC\(\gamma1\) in R-VTA causes increased preference for sucrose and increased anxiety-like behavior but does not affect responses to stress or nociceptive stimuli. In contrast, overexpression of PLC\(\gamma1\) in C-VTA decreases preference for sucrose and increases sensitivity to stress and nociceptive stimuli, although there was a tendency for increased anxiety-like behavior as seen for the R-VTA. These results show that levels of PLC\(\gamma1\) in the VTA regulate responsiveness to drugs of abuse, natural rewards, and aversive stimuli and point to the possibility that distinct topographical regions within the VTA mediate generally positive versus negative responses to emotional stimuli. Moreover, these data also support a role for drug-induced elevations in PLC\(\gamma1\) expression in the VTA in mediating long-term adaptations to drugs of abuse and aversive stimuli.

Key words: growth factors; neural plasticity; viral-mediated gene transfer; drug addiction; morphine; stress; depression

Introduction

Neurotrophic factors and the signaling pathways they activate are best characterized for promoting growth, differentiation, and survival of neurons during development. More recently, these factors have been implicated as mediators of neuronal maintenance and plasticity in the adult nervous system (Barde, 1989; Lindsay et al., 1994; Patterson et al., 1996; Lu and Figurov, 1997). Neurotrophic factor levels are altered during aging and in models of neurodegeneration and neuropsychiatric disorders, whereas intracranial infusions of neurotrophic factors can have palliative effects in these models (Gash et al., 1996; Nestler et al., 1996; Duman et al., 1997; Hellweg et al., 1998; Smith et al., 1999).

The mesolimbic dopamine system, which consists of dopamine neurons in the ventral tegmental area (VTA) and their projections to the nucleus accumbens (NAc) (a major efferent region of the VTA) and other limbic regions, is a major substrate believed to regulate motivated behavior and responses to natural reinforcers such as food and sex (Di Chiara and North, 1992; Kelley and Berridge, 2002). Drugs of abuse potently activate this pathway and, after repeated administration, cause long-term adaptations in VTA dopamine neurons and their targets (Wise, 1996; Koob et al., 1998; Nestler, 2001). Among other adaptations, VTA dopamine neurons show increased levels of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis (Beitner-Johnson and Nestler, 1991; Sorg et al., 1993), and they become smaller (Sklair-Tavron et al., 1996) and have diminished levels of neurofilament proteins and axoplasmic transport to the NAc (Beitner-Johnson et al., 1992; Beitner-Johnson and Nestler, 1993).

Some of these biochemical and morphological adaptations of VTA dopamine neurons after chronic drug exposure are similar to changes seen \textit{in vitro} and \textit{in vivo} after neuronal injury or reduced neurotrophic support (Nestler et al., 1996). Evidence for this premise comes from studies showing that infusion of certain neurotrophic factors into the VTA opposes the effects of drugs of abuse on these neurons (Berhow et al., 1995, 1996; Sklair-Tavron et al., 1996; Messer et al., 2000). Moreover, chronic morphine exposure alters levels of specific neurotrophic factor-signaling proteins in this brain region (Ortiz et al., 1995; Berhow et al.,...
1996), for example, phospholipase Cγ1 (PLCγ1) (Wolf et al., 1999). Of the known PLC isoforms, only PLCγ is activated directly by neurotrophic factors (Rhee, 2001) and, of PLCγ isoforms, only PLCγ1 is expressed in brain (Ross et al., 1989). Unlike PLCγ, PLCβ and PLCδ are not regulated by morphine (Wolf et al., 1999).

Despite the evidence that chronic morphine induces PLCγ1 in the VTA, the functional consequences of this effect have remained unknown. The present study was designed to address this question by examining the effect of increased PLCγ1 expression in this region, achieved with viral-mediated gene transfer, on behavioral responses to morphine and other emotional stimuli.

Materials and Methods

Animals. Male Sprague Dawley rats (Charles River, Kingston, NY), weighing 350–375 g at the start of the experiment, were used in this study. All animals were habituated to the animal facility for at least 1 week before experimental manipulation. Rats were double housed in clear polypropylene boxes containing wood shavings in an animal colony maintained at 23–25°C on a 12 h light/dark cycle in which lights are on between 7:00 A.M. and 7:00 P.M. All animals were provided with food and water ad libitum. Experiments were conducted in accordance with guidelines of the Society for Neuroscience and the institutional animal review committee of The University of Texas Southwestern (Dallas, TX).

Viral vectors. cDNAs for PLCγ1 (obtained from S. G. Rhee, National Institutes of Health, Bethesda, MD) and LucZ were inserted into the herpes simplex virus (HSV) amplicon HSV–PrPUC and packaged into virus using the helper vector Sd1.2, as described previously (Neve et al., 1997). The average titer of the recombinant virus stocks was 4.0 × 10^7 infectious units/ml. Titers did not differ by >10% among preparations. All behavioral experiments were commenced on day 3 after viral surgery, a time at which maximal transgene expression caused by these vectors was observed (Carlezon et al., 1998). Expression of the HSV-encoded transgene is limited to an area of ~1 mm around the injection site, and no expression is seen in either efferent or afferent regions of the injected area. Thus, we found no detectable PLCγ1 or LucZ expression in either the NAc or the dorsal raphe (a major afferent region of the VTA).

Animal surgery. For viral injections in rats, animals were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and given atropine (0.25 mg/kg, s.c.) to minimize bronchial secretions. Afterward, animals were given sodium pentobarbital (60 mg/kg, i.p.) and atropine (0.25 mg/kg, s.c.). Rats were immobilized with a grid floor (Barrot et al., 2002). The threshold of foot-shock intensity required to induce a behavioral response was determined. After 2 min of habituation to the testing chamber, rats received a foot shock consisting of a 2.0 mA current for 2.0 sec. If rats did not display a clear response, the intensity of the foot shock was increased by 0.05 mA until a response was observed. This procedure was repeated until the threshold of foot shock was determined (Porsolt et al., 1977; Cryan et al., 2002). Rats received HSV–PLCγ1, HSV–LucZ, or sham surgery injections into R-VTA or C-VTA. On day 3 after surgery, the sucrose preference test was repeated exactly as performed on day 5 of baseline.

In the absence of a behavioral response, the intensity of the foot shock was increased by 0.05 mA until a response was observed. This procedure was repeated until the threshold of foot shock was determined (Porsolt et al., 1977; Cryan et al., 2002). Rats received HSV–PLCγ1, HSV–LucZ, or sham surgery injections into R-VTA or C-VTA as described above. On day 3 after surgery, rats were placed in plastic cylinders (30 × 45 cm) filled to 30 cm depth (so that the paws and tail do not touch the bottom) with 25°C water and forced to swim for 15 min. At the end of this period, rats were removed from the water, dried with towels, and kept in a warm enclosure for 30 min. All cylinders were emptied and cleaned between rats. Twenty-four hours after the forced swim, rats were retested for 5 min under identical conditions, and sessions were videotaped by a camera attached to the ceiling of the testing room. Raters unaware of the treatment conditions scored the videotapes. In this study, the latency to become immobile was the dependent variable. Latency to immobility was defined as the time at which the rat first initiated a stationary posture that did not reflect attempts to escape from the water (Lücki, 1997; Plaas et al., 2001). To qualify as immobility, this posture had to be clearly visible and maintained for ≥2.0 sec.

Locomotor activity. A separate group of rats was used to examine whether gene transfer treatments affected general locomotor activity 24 hr after day 1 of forced swimming. Rats received HSV microinjections or sham surgery into R-VTA or C-VTA and were placed for 1 hr in automated (75 cm diameter × 15 cm wide, four photocell beams) circular activity chambers (Med Associates).

Response to nociceptive stimuli. In this test, we exposed rats to an electric foot-shock session in an apparatus consisting of a computerized box with a grid floor (Barrot et al., 2002). The threshold of foot-shock intensity required to induce a behavioral response was determined. After 2 min of habituation to the testing chamber, rats received a foot shock consisting of a 2.0 mA current for 2.0 sec. If rats did not display a clear response, the intensity of the foot shock was increased by 0.05 mA until a response was observed (to a maximum of 1.0 mA). The first appearance of a flinch, an audible vocalization, and a jump were recorded. The test session was terminated after all three behavioral responses were observed in each animal.

Elevated-plus maze. Rats receiving HSV microinjections or sham surgery into R-VTA or C-VTA were tested for 5 min on the elevated-plus maze, a behavioral test of anxiety-like behavior. The maze was made of gray plastic and consisted of two perpendicular, intersecting runways (12 cm wide × 100 cm long) (Barrot et al., 2002). One runway had tall walls (40-cm-high “closed arms”), whereas the other one had no walls (“open arms”). The arms were connected by a central area, and the maze was elevated 1 m from the floor. Testing was conducted between 9:00 A.M. and 1:00 P.M. under controlled light conditions (~90 lux). At the begin-
Figure 1. Viral-mediated gene transfer. A, B, Rostral and caudal regions of the VTA to which microinjections of HSV vectors and sham surgery were targeted. C, D, Expression of β-gal (C), revealed by X-Gal (5-bromo-4-chloro-3-indoly-β-D-galactopyranoside) assay and PLCγ1 (D), revealed by fluorescence immunohistochemistry (magnification, 20×) 3 d after microinjections of HSV–LacZ or HSV–PLCγ1 into the left VTA. E, Adjacent, Nissl-stained section from the same brain section in D, showing lack of gliosis in the region of transgene expression. F–H, HSV–LacZ microinjection did not alter PLCγ1 levels in the VTA. For example, no colocalization of β-gal (F) and PLCγ1 (G) was observed (merged image in H; magnification, 40×) after a microinjection of HSV–LacZ in the VTA. A comparison of D and G shows the degree of PLCγ1 overexpression achieved with HSV–PLCγ1 microinjections. I–K, Confocal photomicrographs (magnification, 400×) of a representative brain slice from the C–VTA (−5.8 mm caudal to bregma) double labeled for TH and PLCγ1 to determine the percentage of infected cells that were dopaminergic. I, Cells expressing TH represented by green (Cy2) fluorescence. J, Cells expressing PLCγ1 represented by red (Cy3) fluorescence. K, Merged confocal image of I and J showing that five of the eight brightly labeled PLCγ1 cells (60%) are double labeled, represented by yellow fluorescence. Arrows indicate colabeled cells.

Results

Viral-mediated gene transfer in the VTA

Figure 1, A and B, shows the R-VTA and C-VTA to which microinjections of HSV vectors (HSV–LacZ or HSV–PLCγ1) were aimed, and Figure 2 shows the range of injected rostral and caudal regions targeted in a typical experiment. We separately targeted rostral and caudal subregions of the VTA on the basis of previous evidence that manipulation of the two regions can differentially regulate morphine reward (Carlezon et al., 2000b). As reported previously for HSV–LacZ and several other HSV vectors (Carlezon et al., 1997, 1998, 2000b; Barrot et al., 2002), we found that expression of LacZ (Fig. 1C) and PLCγ1 (Fig. 1D) was maximal between days 3 and 4 after virus injection, and it significantly declined thereafter as a result of the transient nature of transgene expression (Neve et al., 1997). Viral-mediated expression was restricted to an area of the VTA of ~1 mm in diameter and was accompanied by minimal damage (Fig. 1E) that was indistinguishable from that caused by microinjection of vehicle alone (10% surose). No change in PLCγ1 immunoreactivity was present in rats given HSV–LacZ microinjections, confirming that increased PLCγ1 expression in HSV–PLCγ1-treated animals is not a nonspecific reaction to surgery or viral infection (Fig. 1F–H). Confocal microscopy (Fig. 1I–K) revealed that 52% of the neurons overexpressing PLCγ1 in R-VTA were dopaminergic (i.e., TH positive), whereas in C-VTA, 65% of the PLCγ1-infected neurons were double labeled. This difference, which is similar to previous findings (Carlezon et al., 2000b), did not reach statistical significance (p > 0.1). As found in previous studies using HSV vectors, we found no detectable expression of the viral-encoded transgenes in glial cells (data not shown).

PLCγ1 regulation of morphine-conditioned place preference

Conditioned place preference has been widely used to assess the rewarding or aversive properties of drugs. In this behavioral assay, animals learn to prefer environments associated previously with reward (Carlezon et al., 2000b). As reported previously for HSV–LacZ and several other HSV vectors (Carlezon et al., 1997, 1998, 2000b; Barrot et al., 2002), we found that expression of LacZ (Fig. 1C) and PLCγ1 (Fig. 1D) was maximal between days 3 and 4 after virus injection, and it significantly declined thereafter as a result of the transient nature of transgene expression (Neve et al., 1997). Viral-mediated expression was restricted to an area of the VTA of ~1 mm in diameter and was accompanied by minimal damage (Fig. 1E) that was indistinguishable from that caused by microinjection of vehicle alone (10% surose). No change in PLCγ1 immunoreactivity was present in rats given HSV–LacZ microinjections, confirming that increased PLCγ1 expression in HSV–PLCγ1-treated animals is not a nonspecific reaction to surgery or viral infection (Fig. 1F–H). Confocal microscopy (Fig. 1I–K) revealed that 52% of the neurons overexpressing PLCγ1 in R-VTA were dopaminergic (i.e., TH positive), whereas in C-VTA, 65% of the PLCγ1-infected neurons were double labeled. This difference, which is similar to previous findings (Carlezon et al., 2000b), did not reach statistical significance (p > 0.1). As found in previous studies using HSV vectors, we found no detectable expression of the viral-encoded transgenes in glial cells (data not shown).

PLCγ1 regulation of morphine-conditioned place preference

Conditioned place preference has been widely used to assess the rewarding or aversive properties of drugs. In this behavioral assay, animals learn to prefer environments associated previously
with rewarding drug effects, while they avoid environments associated with aversive drug effects (Hoffman, 1989). As seen in Figure 3A, time spent in the morphine-paired compartment varied as a function of viral vector treatment and VTA region (viral treatment × region interaction, $F_{(2,107)} = 9.2; p < 0.0002$). Animals receiving HSV–PLCγ1 injections into the R-VTA spent significantly more time in environments paired with threshold doses of morphine [0.25 ($p = 0.06$) and 0.50 ($p = 0.04$) mg/kg], whereas rats with PLCγ1 microinjections into the C-VTA did not consistently approach the morphine-paired environments when compared with their HSV–LacZ or sham controls. In fact, microinjecting HSV–PLCγ1 into the C-VTA resulted in avoidance of the morphine-paired compartments [0.25 ($p = 0.001$) and 0.50 ($p = 0.0001$)]. Both the increased reward seen with PLCγ1 overexpression in R-VTA and the aversion seen with PLCγ1 overexpression in C-VTA showed a clear dose response. In contrast, microinjections of HSV–PLCγ1 into the nearby substantia nigra did not make these doses of morphine rewarding or aversive (data not shown).

**PLCγ1 regulation of sucrose preference**
To generalize the place-conditioning effects of PLCγ1 in the VTA to a natural reward, and to a behavioral paradigm free of associative memory, we studied sucrose preference. Overall analysis indicated that HSV microinjections did not significantly affect the total fluid intake of the rats (water plus sucrose) (Fig. 3B) during the testing day. However, similar to the effects seen with morphine place conditioning, sucrose preference varied as a function of VTA region, viral treatment, and testing (viral treatment × region × test day interaction, $F_{(2,106)} = 3.7; p < 0.02$). PLCγ1 overexpression in R-VTA increased sucrose preference when compared with pretesting scores ($p < 0.003$) and with the LacZ ($p < 0.05$) and sham ($p < 0.05$) control groups during the test day (Fig. 3B). Conversely, PLCγ1 overexpression in C-VTA showed a notable, although marginally significant ($p = 0.065$), decrease in sucrose preference when compared with their sucrose scores at pretest and a significant difference when compared with preference scores for the HSV–LacZ ($p < 0.05$) or sham ($p < 0.05$) groups. As an additional control, we found that HSV–PLCγ1 microinjections into the substantia nigra did not affect sucrose preference (data not shown).

**PLCγ1 regulation of forced swimming**
Given the increasing evidence that the mesolimbic dopamine system regulates responses to aversive stimuli as well as rewarding ones (Barrot et al., 2002), it was of interest to study the effect of PLCγ1 overexpression in behavioral tests of aversion. We first used the forced swim test to study animal responses to stressful conditions (Pliakas et al., 2001; Cryan et al., 2002). In this test, animals initially struggle trying to escape, but within 1 or 2 min, they become immobile. The amount of time rats engaged in escape-directed behaviors (i.e., latency to immobility) in the forced swim test was dependent on viral treatment. Animals receiving HSV–PLCγ1 into the C-VTA had significantly shorter times to become immobile (treatment main effect, $F_{(2,13)} = 5.2; p < 0.02$) than rats receiving sham ($p < 0.014$) or HSV–LacZ ($p < 0.017$) microinjections into the C-VTA (Fig. 4A). In contrast, no difference in the latency to immobility was apparent in animals receiving HSV–PLCγ1 into the R-VTA. To assess whether the effects observed in the forced swim test could be confounded by changes in general locomotor activity after viral-mediated gene transfer, separate groups of HSV–PLCγ1, HSV–LacZ, or sham surgery animals were analyzed for locomotor behavior. As seen in Figure 4B, no significant differences were apparent during PLCγ1 overexpression in either the C-VTA or R-VTA ($F_{(2,24)} = 1.6; p > 0.2$), when locomotor activity was assessed 24 hr after day 1 of forced swimming (day 4 after HSV microinjections). HSV–PLCγ1 microinjections into the substantia nigra did not alter the responses of the animals in the forced swim test (data not shown).

**PLCγ1 regulation of responses to nociceptive stimuli**
Our findings thus far show that PLCγ1 overexpression in the R-VTA and C-VTA can differentially modulate behavioral responses to rewarding and stressful stimuli. We next assessed the influence of PLCγ1 overexpression in the VTA on unconditioned behavioral responses to nociceptive stimuli. When compared with control groups, overexpression of PLCγ1 in the C-VTA decreased the threshold foot-shock intensities required to elicit vocalization ($F_{(1,42)} = 6.37; p < 0.05$) or jumping ($F_{(1,42)} = 8.43; p < 0.001$) without significantly affecting the threshold intensity eliciting a flinch reaction (Fig. 5A). These data suggest that animals receiving HSV–PLCγ1 into the C-VTA are more sensitive to this mild nociceptive stimulus. In contrast, animals receiving HSV–PLCγ1 into the R-VTA showed no difference in nociceptive responses (Fig. 5A).

**PLCγ1 regulation of elevated-plus maze behavior**
We also studied the effect of PLCγ1 overexpression in the R-VTA and C-VTA on anxiety-like behavior using the elevated-plus maze. Time spent in the open arms of the plus maze (a measure of anxiety-like behavior) was affected by viral treatment (condition main effect, $F_{(2,36)} = 8.51; p < 0.0009$), but it did not vary as a function of VTA region (Fig. 5B). Animals receiving HSV–PLCγ1 in R-VTA spent significantly less time in the open arms of the maze than the HSV–LacZ ($p = 0.01$) and sham ($p = 0.005$) controls, an indication of increased anxiety-like behavior. However, there was a trend for a similar decrease in time spent on the open arms in rats microinjected with HSV–PLCγ1 in C-VTA compared with the HSV–LacZ or sham controls ($p = 0.065$ in each case).

**Discussion**
Previous reports have implicated neurotrophic factors in the cellular and behavioral adaptations occurring in the VTA after prolonged exposure to drugs of abuse (see Introduction). Moreover, chronic exposure to drugs of abuse has been shown to alter several components of neurotrophic factor-signaling cascades
One example was our demonstration that repeated exposure to morphine increases levels of PLC in the VTA (Wolf et al., 1999). Although PLC has been implicated in mediating several neurobiological processes (Kamat and Carpenter, 1997; Rhee, 2001), the functional role this signaling protein plays in mediating responses to drugs of abuse has remained unknown. Thus, in the present study, we mimicked the biological response of PLC induction observed after chronic morphine by using viral-mediated gene transfer to locally increase PLC levels in the VTA. We showed that increased expression of PLC in the VTA modulates behavioral responses to morphine and to sucrose (a natural reward), as well as several aversive stimuli.

Figure 3. PLC regulates responses to rewarding stimuli. A, Morphine (0.125, 0.25, and 0.50 mg/kg, s.c.) place conditioning. PLC overexpression in R-VTA enhanced sensitivity to threshold doses of morphine, whereas overexpression of this protein in C-VTA resulted in place aversion. Sham surgery and β-gal expression (via HSV–LacZ) had no effect on place conditioning. * p < 0.05; † p = 0.06. B, Sucrose preference. Sham surgery and β-gal expression did not affect sucrose preference, regardless of VTA region. PLC overexpression in R-VTA significantly increased sucrose preference, whereas PLC in C-VTA decreased sucrose preference, respectively. Data are presented as percentage difference of total liquid intake between pretest and posttest (top) or as difference in liquid intake between sucrose and water bottle (bottom). PLC overexpression did not affect total fluid (sucrose plus water) intake (bottom). * p < 0.05; † p = 0.065. Error bars indicate SEM.

Figure 4. PLC regulates responses to swim stress. A, Latencies to become immobile varied as a function of viral vector treatment and VTA region. Latencies were significantly decreased in rats treated with HSV–PLC in C-VTA. HSV–LacZ or sham injections had no effect. Data are presented as latencies (mean ± SEM, in seconds) during the 5 min test on day 4 after HSV microinjections. B, There were no group differences when activity, rather than swimming, was quantified during testing day. * p < 0.002. Error bars indicate SEM.
in their responses to foot shock. Regulation of these behavioral re-

cponses elicited by emotional stimuli is dependent on the subre-

addition, we showed that regulation of these behavioral re-

ponses elicted by emotional stimuli is dependent on the subre-

region of the VTA in which PLCγ1 is overexpressed.

Our findings describe two distinct behavioral phenotypes

cased by PLCγ1 overexpression in the rostral versus caudal as-

pects of the VTA. In the R-VTA, increased levels of PLCγ1 in-

creased the sensitivity of an animal to the rewarding effects of

orphine as well as the sucrose preference of an animal, while

causing little change in its responses to aversive stimuli. In con-

trast, in the C-VTA, increased levels of PLCγ1 cause the opposite
effects on reward, with reduced responses to morphine and suc-

crose observed, but also induce greater sensitivity to several types

of aversive stimuli, including swim stress and nociceptive and

anxiogenic challenges. These data thereby suggest two distinct

functional loops mediated by drug-induced upregulation of

PLCγ1 expression in rostral and caudal subregions of the VTA. In

the R-VTA, upregulation of PLCγ1 would appear to mediate a

state of sensitized responses to drug and natural rewards. In con-

trast, in the C-VTA, upregulation of PLCγ1 would appear to

mediate a depressed emotional state characterized by reduced

sensitivity to reward and enhanced sensitivity to negative emo-

tional stimuli.

The opposite effects of PLCγ1 overexpression in R-VTA ver-
sus C-VTA on measures of drug reward are in agreement with

several previous studies that have demonstrated that topographi-
cal differences within the VTA mediate the rewarding and aver-
sive properties of drugs (Ikemoto et al., 1997, 1998; Carlezon et

al., 2000b; Olson et al., 2001), and we now extend these previous

findings to a natural reward, namely sucrose. Although the mech-

anisms underlying these topographical differences remain un-

known, two explanations have been offered. The first speculates

that distinct populations of dopamine neurons within the VTA

might mediate the divergent behavioral effects observed between

R-VTA and C-VTA. Neuroanatomical studies indicate that do-
pamine neurons from more rostral portions of the VTA innervate

primarily, but not exclusively, the NAc shell, whereas dopamine

neurons from C-VTA project predominantly, but not exclu-

sively, to cortical areas (Emson and Koob, 1978; Brog et al., 1993).

Moreover, these projections show differential regulation by mor-

phine: morphine increases extracellular dopamine levels in the

NAc shell but has no effect in prefrontal cortical areas (Bassareo

et al., 1996), whereas morphine withdrawal is associated with
decreased extracellular dopamine levels in the NAc shell but in-
creased levels in prefrontal cortex (Acquas et al., 1991; Pothos et

al., 1991; Bassareo et al., 1995). Thus, within this framework, it is

conceivable that increased PLCγ1 activity in R-VTA dopamine

neurons enhances reward to morphine and sucrose while result-

ing in opposite effects when PLCγ1 activity is enhanced in C-

VTA dopamine neurons.

The second explanation focuses on distinct populations of

nondopaminergic, most likely GABAergic, neurons in the

R-VTA versus C-VTA, which differentially regulate drug and su-
crose reward. GABAergic neurons in the VTA have long been

known to regulate the activity of VTA dopamine neurons (Di

Chiara and North, 1992; Johnson and North, 1992) and, more

recently, have been shown to project directly to the NAc (Van

Bockstaele and Pickel, 1995; Steffensen et al., 1998), thereby pro-

viding two mechanisms by which these neurons control activity

of the mesolimbic reward pathway. GABAergic activity in the

VTA has been shown to play an increasingly important role in

modulating the behavioral and cellular responses to rewarding

(Roberts and Brebner, 2000; Laviollette and van der Kooy, 2001;

Steffensen et al., 2001) and aversive (Bonci and Williams, 1997;

Chieng and Williams, 1998) stimuli. The HSV vectors used in this

study are not selective for a particular type of neuron (Neve et al.,

1997; Carlezon et al., 2000a), and appear to infect all neuronal

types within a given brain region with approximately equal effi-

ciency. However, because the density of dopaminergic neurons

in the VTA decreases from caudal to rostral subregions, it is possible

that PLC-γ1 overexpression may occur to a greater extent in

nondopaminergic cells in the R-VTA compared with the C-VTA.

Indeed, whereas a clear majority of HSV-infected cells in the

Figure 5. PLCγ1 regulates responses to nociceptive and anxiogenic stimuli. A, Rats with

HSV–PLCγ1 overexpression in C-VTA vocalized and jumped in response to lower foot-shock

intensities than rats overexpressing PLCγ1 in R-VTA. HSV–LacZ and sham groups did not differ

in their responses to foot shock. B, Animals overexpressing PLCγ1 in R-VTA spent significantly

less time in the open arms of the elevated-plus maze than the LacZ and sham controls. There

was a trend, although not statistically significant, for decrease in time spent in the open arms in

rats overexpressing PLCγ1 in C-VTA compared with their respective LacZ and sham controls.

*p < 0.05. Error bars indicate SEM.
C-VTA are dopaminergic (i.e., TH positive), a somewhat smaller percentage of infected cells in the R-VTA are dopaminergic. However, additional work is needed to determine whether this difference in PLC-yl overexpression in dopaminergic versus nondopaminergic cells between R-VTA and C-VTA can explain the differential behavioral effects observed. In addition, it will be important in future investigations to determine whether the morphine-induced upregulation of PLC-yl occurs predominantly in dopaminergic, nondopaminergic, or both cell types in the VTA. GABAergic neurons are a likely candidate for the nondopaminergic cells involved in this phenomenon. Unfortunately, it has not been possible to directly identify cell bodies of these neurons in the VTA because of limitations in available antibodies.

Our findings that PLC-yl overexpression in the C-VTA alters the sensitivity of an animal to aversive stimuli lends additional support to the notion that the mesolimbic reward pathway may play a role in the symptoms of depression and other stress-related syndromes (Kapur and Mann, 1992; Naranjo et al., 2001; Pliakas et al., 2001; Yadid et al., 2001; Nestler et al., 2002). Thus, animals that received HSV–PLC-yl injections in the C-VTA exhibited shorter latency to immobility in the forced swim test, an effect opposite to that of antidepressant treatments (Cryan et al., 2002). In contrast, microinjections of HSV–PLC-yl into R-VTA had no effect on this test. The decreased latency to immobility obtained with HSV–PLC-yl injections in the C-VTA was not caused by changes in general motor activity, which was unaffected by PLC-yl overexpression. Additionally, sham treatment or injection of HSV–LacZ into the C-VTA did not affect latency to immobility, indicating that surgery or viral infection per se does not affect forced swimming. Additional studies with foot–shock stress and the elevated-plus maze found that PLC-yl overexpression in the C-VTA increased the responses of the animals to nociceptive and anxiogenic stimuli. Thus, the induction of PLC-yl in C-VTA, by decreasing responses to rewarding stimuli while increasing responses to aversive stimuli, could contribute to a similar constellation of symptoms, which are seen in many drug addicts, particularly during early phases of drug withdrawal (Gawin and Kleber, 1986; Gawin et al., 1989; Barr et al., 2002). It also would be interesting to investigate the possible involvement of PLC-yl in the C-VTA in the rat now in mediating these and certain other symptoms of depression (American Psychiatric Association, 1994).

To summarize, results of the present study establish the functional importance of morphine-induced upregulation of PLC-yl expression in the VTA. Our findings define two distinct feedback loops whereby PLC-yl induction in R-VTA versus C-VTA mediate distinct behavioral adaptations to chronic morphine exposure. Additional understanding of the mechanisms underlying this PLC-yl-induced behavioral plasticity will lead to a better understanding of the neural and molecular basis of drug addiction.

References